The Global Lewy Body Dementia (LBD) Drugs Market reports is now available at Contrive Datum Insights (CDI).
LBD, aka dementia with Lewy bodies, is the second most common type of progressive dementia after Alzheimer’s disease dementia, according to Mayo Clinic.
In this condition, protein deposits, known as Lewy bodies, develop in nerve cells or neurons in the brain, especially in the regions that are associated with thinking, memory, and movement.
LBD causes a progressive decline in mental abilities, according to Mayo Clinic. Patients with LBD may experience changes in attention or alertness and visual hallucinations. Other symptoms are similar to Parkinson’s disease, such as tremors, involuntary slow movements, and rigid muscles.
It is estimated that nearly 1.4 million Americans, aged 50 or above, have LBD, according to Lewy Body Dementia Resource Center.
The Global Lewy Body Dementia Drugs Market report contains primary and secondary research methodologies, which has been summarized with market insights so you can have a complete understanding of the subject matter.
CDI said the report has different sections to offer you the data concisely and professionally.
Some of the key industry players include Pfizer, Novartis, Bayer, GlaxoSmithKline, Sanofi, Mylan, Johnson & Johnson, Teva, Eli Lilly, Eisai, among others.
The report highlights crucial trends and dynamics that have an impact on the development of the global LBD market, including market growth, market size and share, key drivers, and opportunities.
Furthermore, the report offers data based on the target market, key geographical regions, key industry players, market segments, and selling strategies.
The Global LBD Drugs Market segmentation is based on drugs such as modafinil (Provigil), benzodiazepines (Valium and Xanax), antidepressants, cholinesterase inhibitors such as donepezil (Aricept), antipsychotic drugs, such as carbidopa/levodopa.
The report covers regions such as North American, South American, Europe, Asia-Pacific, the Middle East and Africa.
The Global LBD Market report also contains the market forecast until 2026, with an analytical view on the trends and platforms for boosting the LBD drugs businesses. CDI is one of the global delivery partners of market intelligence and consulting services. It offers industry knowledge coupled with global- and country-level expertise.
